CN103599084A - 一种降压组合物 - Google Patents
一种降压组合物 Download PDFInfo
- Publication number
- CN103599084A CN103599084A CN201310616630.7A CN201310616630A CN103599084A CN 103599084 A CN103599084 A CN 103599084A CN 201310616630 A CN201310616630 A CN 201310616630A CN 103599084 A CN103599084 A CN 103599084A
- Authority
- CN
- China
- Prior art keywords
- valsartan
- lactose
- polyvinylpolypyrrolidone
- glyceryl monostearate
- tablet composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 9
- 230000003276 anti-hypertensive effect Effects 0.000 title 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims abstract description 40
- 229960004699 valsartan Drugs 0.000 claims abstract description 40
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims abstract description 39
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 27
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 19
- 239000008101 lactose Substances 0.000 claims abstract description 19
- 239000011248 coating agent Substances 0.000 claims abstract description 16
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 12
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 12
- 239000007916 tablet composition Substances 0.000 claims abstract description 12
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 6
- 239000002245 particle Substances 0.000 claims abstract description 6
- 238000000576 coating method Methods 0.000 claims description 15
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 13
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 11
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000000889 atomisation Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 13
- 238000005516 engineering process Methods 0.000 abstract description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- -1 Valsartan compound Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310616630.7A CN103599084B (zh) | 2013-11-22 | 2013-11-22 | 一种降压组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310616630.7A CN103599084B (zh) | 2013-11-22 | 2013-11-22 | 一种降压组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103599084A true CN103599084A (zh) | 2014-02-26 |
CN103599084B CN103599084B (zh) | 2018-10-30 |
Family
ID=50117393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310616630.7A Active CN103599084B (zh) | 2013-11-22 | 2013-11-22 | 一种降压组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103599084B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103933000A (zh) * | 2014-05-06 | 2014-07-23 | 山东新时代药业有限公司 | 一种阿齐沙坦片剂及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1437469A (zh) * | 2000-06-22 | 2003-08-20 | 诺瓦提斯公司 | 药物组合物 |
CN101087589A (zh) * | 2004-12-24 | 2007-12-12 | 新梅斯托克尔克公司 | 含有缬沙坦的固体药物组合物 |
CN101167723A (zh) * | 2006-10-27 | 2008-04-30 | 陈益智 | 缬沙坦分散片及其制备方法 |
CN102204907A (zh) * | 2011-03-31 | 2011-10-05 | 北京赛科药业有限责任公司 | 一种含缬沙坦的药物组合物及其制备方法 |
US20120107397A1 (en) * | 2009-07-03 | 2012-05-03 | Hetero Research Foundation | Pharmaceutical compositions of valsartan |
-
2013
- 2013-11-22 CN CN201310616630.7A patent/CN103599084B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1437469A (zh) * | 2000-06-22 | 2003-08-20 | 诺瓦提斯公司 | 药物组合物 |
CN101087589A (zh) * | 2004-12-24 | 2007-12-12 | 新梅斯托克尔克公司 | 含有缬沙坦的固体药物组合物 |
CN101167723A (zh) * | 2006-10-27 | 2008-04-30 | 陈益智 | 缬沙坦分散片及其制备方法 |
US20120107397A1 (en) * | 2009-07-03 | 2012-05-03 | Hetero Research Foundation | Pharmaceutical compositions of valsartan |
CN102204907A (zh) * | 2011-03-31 | 2011-10-05 | 北京赛科药业有限责任公司 | 一种含缬沙坦的药物组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
江芸: "单硬脂酸甘油醋的生产及应用", 《杭州化工》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103933000A (zh) * | 2014-05-06 | 2014-07-23 | 山东新时代药业有限公司 | 一种阿齐沙坦片剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103599084B (zh) | 2018-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101665968B1 (ko) | 구연산철 투여형태 | |
CN104146976A (zh) | 一种高负载丙戊酸类药物缓释片及其制备方法 | |
CA3123774C (en) | Transdermal psychoactive alkaloid composition and preparation thereof | |
CN107693515B (zh) | 含碱化剂和艾曲泊帕的药物组合物及其用途 | |
JP2014224079A (ja) | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 | |
JP7007300B2 (ja) | ダパグリフロジンの新規な結晶形並びにその製造方法および用途 | |
CN103655505A (zh) | 一种止痛类双层控释片及其制备方法 | |
CN102772395A (zh) | 含有盐酸氨溴索和盐酸克仑特罗的缓释制剂及其制备方法 | |
CN103599084A (zh) | 一种降压组合物 | |
JP2009528301A (ja) | アンドログラフィス抽出物製剤 | |
CN109481437B (zh) | 一种氯沙坦钾药物制剂 | |
CN103845332B (zh) | 一种达沙替尼药用组合物及其制备方法 | |
CN103860511B (zh) | 一种含有厄贝沙坦和苯磺酸氨氯地平的药用组合物及其制备方法 | |
JPS618A (ja) | ニフエジピン含有製剤 | |
CN1762354B (zh) | 一种含有钙阻滞剂的稳定药物组合物 | |
CN102058602B (zh) | 一种稳定的含氯沙坦钾和氢***的口服固体制剂 | |
CN104644632A (zh) | 含有阿齐沙坦和苯磺酸氨氯地平的口服片剂及其制备方法 | |
RU2007147953A (ru) | Фармацевтические рецептуры микронизированного (4-хлорфенил)[4-(4-пиридилметил)-фталазин-1-ила] и его солей с немедленным высвобождением и высоким содержанием лекарственного средства | |
CN104644601B (zh) | 一种卡培他滨片剂 | |
CN104138363A (zh) | 一种硝苯地平缓释片及其制备方法 | |
CN104337783B (zh) | 一种卡培他滨片剂及其制备方法 | |
CN113648284B (zh) | 一种含有沙库巴曲缬沙坦钠的片剂及其制备方法 | |
JP4696210B2 (ja) | イソソルビド‐5‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法 | |
KR101509489B1 (ko) | 발사르탄을 함유하는 고형 경구제형의 제조 방법 | |
US20160022661A1 (en) | Dosage Form Comprising Crizotinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB02 | Change of applicant information |
Address after: 264205, Weihai economic and Technological Zone, Shandong Province, Qingdao South Road, No. 1 Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Applicant after: Shandong Disha Pharmaceutical Co.,Ltd., Disha Phamaceutical Group Applicant after: WEIHAI DIJIA PHARMACEUTICAL Co.,Ltd. Address before: 264205, Weihai economic and Technological Zone, Shandong Province, Qingdao South Road, No. 1 Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: Shandong Disha Pharmaceutical Co.,Ltd., Disha Phamaceutical Group Applicant before: WEIHAI DIJIA FINE CHEMICAL Co.,Ltd. |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160623 Address after: Economic and Technological Development Zone of Shandong Province, Weihai City, Gushan Town, 264000 No. 18 South Road, No. 19 North Road, No. 3 East Road, the west five Applicant after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 264205, Weihai economic and Technological Zone, Shandong Province, Qingdao South Road, No. 1 Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: Shandong Disha Pharmaceutical Co.,Ltd., Disha Phamaceutical Group Applicant before: WEIHAI DIJIA PHARMACEUTICAL Co.,Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191024 Address after: 264205 Guangzhou East Road South and an East Road East, Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Co-patentee after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Co-patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: Economic and Technological Development Zone of Shandong Province, Weihai City, Gushan Town, 264000 No. 18 South Road, No. 19 North Road, No. 3 East Road, the west five Co-patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210906 Address after: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 264205 Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Patentee before: Dijia Pharmaceutical Group Co.,Ltd. Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Effective date of registration: 20210906 Address after: 264205 Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 264205 Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Patentee before: Dijia Pharmaceutical Group Co.,Ltd. Patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A pressure reducing composition Effective date of registration: 20220721 Granted publication date: 20181030 Pledgee: Bank of China Limited Weihai Branch Pledgor: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2022980010828 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |